Ask VialBase
Research

A Study of Retatrutide in Participants With Obesity and Knee Osteoarthritis — VialBase Research

Trial Summary

Phase 3 trial evaluating retatrutide (triple GLP-1/GIP/glucagon receptor agonist) in patients with obesity and symptomatic knee osteoarthritis. Obesity is a major modifiable risk factor for OA progression, and weight loss has established benefits for joint pain and function. Retatrutide, with its triple-agonist mechanism, produces the most weight loss of any incretin-class peptide studied to date.

Design

  • Type: Randomized, double-blind, placebo-controlled, multicenter
  • Population: Adults with BMI 30+ and symptomatic knee OA
  • Arms: Retatrutide vs. placebo
  • Duration: 48-72 weeks
  • Key measures: WOMAC pain and function scores, body weight change, knee MRI structural assessments, inflammatory biomarkers

Key Outcomes

Trial recently completed; full results pending publication. Phase 2 obesity data showed retatrutide achieving up to 24% weight loss at 48 weeks, suggesting substantial mechanical and inflammatory benefit for OA joints.

Significance for Peptide Research

This is the first major trial of a triple-agonist peptide specifically targeting obesity-driven musculoskeletal disease. Retatrutide’s superior weight loss (~24% in Phase 2) could produce OA benefits exceeding those seen with lifestyle intervention alone. If structural joint preservation is demonstrated on MRI, this would represent a paradigm shift from symptom management to disease modification in osteoarthritis. The triple-agonist mechanism (GLP-1 + GIP + glucagon) may also provide direct anti-inflammatory joint effects beyond weight loss.

See Also